New Delhi:
Dr. Reddy’s Laboratories Ltd said on Tuesday it is one of several generic drug companies, including Celgene and Bristol Myers Squibb, that have been subject to antitrust lawsuits in the US.
In a legal filing, the company said a complaint was filed in the New Jersey County, U.S., on Nov. 18, 2022, and has been named as defendants along with other generic drug companies.
The complaint, which purports to be on behalf of a class of indirect purchasers, asserts claims under federal and state antitrust and other state laws alleging that the defendants improperly restricted competition and maintained a shared monopoly in the sale of the brand and generic Revlimid through their respective patent litigation settlements,” said Dr. Reddy’s Laboratories.
Revlimid is a prescription medicine used to treat adults with multiple myeloma (MM) in combination with dexamethasone, or as maintenance treatment after a type of stem cell transplant that uses a person’s own stem cells.
The company said the complaint “alleges that the disputed agreements erroneously delayed generic entry completely until 2022 and then erroneously restricted generic competition until 2026.” The complaint seeks damages for alleged overpayments and equitable relief, it added.
Dr. Reddy’s claimed that “the allegations against it are baseless and will vigorously defend the process”.
(Except for the headline, this story has not been edited by DailyExpertNews staff and is being published from a syndicated feed.)
Featured video of the day
India to strengthen ties with US with greater vigor: Nirmala Sitharaman